|
Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research
|
25 August 2010 |
|
Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox®
|
26 July 2010 |
|
Novartis delivers strong financial performance in second quarter
|
20 July 2010 |
|
Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth
|
02 July 2010 |
|
FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients
|
22 June 2010 |
|
FDA advisory committee recommends approval of Novartis investigational treatment FTY720
|
14 June 2010 |
|
Novartis announces extension of US regulatory priority review period for FTY720
|
28 May 2010 |
|
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME
|
24 May 2010 |
|
Novartis healthcare portfolio generates strong growth in first quarter of 2010
|
27 April 2010 |
|
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products
|
20 April 2010 |